NICE, Alzheimer's and QALY
Taylor, Joseph G.
Clinical Ethics 2007 March; 2(1): 50-54
The introduction of National Institute for Health and Clinical Excellence (NICE) guidance on Alzheimer's medication in November 2006 will have a significant effect on the treatment of patients, and is opposed by the Royal College of Psychiatrists and many charities dealing with the elderly. The use of the Quality-Adjusted Life Year (QALY) in the guidance formulation is much debated due to questions of ageism. This article seeks to examine the basis of these accusations and whether NICE can be justified using a utilitarian calculation in a principally egalitarian system such as the NHS.
Showing items related by title, author, creator and subject.
Taylor, Donald H Jr.; Cook-Deegan, Robert M; Hiraki, Susan; Roberts, J Scott; Blazer, Dan G; Green, Robert C (2010-01)A genetic marker known as apolipoprotein E provides a clear signal of a person's risk of developing Alzheimer's disease and thus that person's future need for long-term care. People who find that they have the variant of ...